The 5th IVI International Congress: Reproductive Medicine and Beyond by ComtecMed 04-Apr-13 to 06-Apr-13 Seville , SPAIN (GYN - Contraception & Reproductive Health)
2013 AIUM Annual Convention by American Institute of Ultrasound in Medicine 06-Apr-13 to 10-Apr-13 New York (New York Marriott Marquis Hotel) , NY USA (CME - Medical Education)
Manejo clínico y terapéutico de la esterilidad. Segundo curso online by Fundacio Dexeus Salud de la Mujer 09-Apr-13 to 31-May-13 online , SPAIN(gynecology)
Pediatric Nursing: Care of the Hospitalized Child by Continuing Education Inc. 10-Apr-13 to 13-Apr-13 Anaheim (Hyatt Regency Orange County) , CA USA (CME - Obstetrics, Gynecology & Women's Health)
Medicina fetal Curso-Taller. Curso de Nivel I y II de la SESEGO by Fundacio Dexeus Salud de la Mujer 15-Apr-13 to 17-Apr-13 Barcelona (Auditorio Salud de la Mujer Dexeus) , SPAIN (OB - Maternal Fetal Medicine)
Female Urology & Urogynecology Symposium (FUUS) by Quadrant HealthCom, Inc 18-Apr-13 to 20-Apr-13 Las Vegas (ARIA) , NV USA (CME - Obstetrics, Gynecology & Women's Health)
Female Urology and Urogynecology Symposium (FUUS) 2013 by Quadrant HealthCom, Inc 18-Apr-13 to 20-Apr-13 Las Vegas (ARIA) , NV USA (CME - Obstetrics, Gynecology & Women's Health)
Like many of my patients, my life revolves around information. Personally, I use the same technology as most of you to keep track of obligations and loved ones. Professionally, the Houston Fertility Center team uses technology and constant communication to manage our patients' treatment plans.
Here's a situation that illustrates how fantastic medical advances don't always translate to patients benefiting in the clinic. For that to happen, the science needs to be carried along a pipeline of practitioner communication, all the way to the patient.
I know what you're thinking: How can an issue like infertility teach us about customizing healthcare? And how can the assisted reproduction field help raise standards in women's healthcare? But it can, and it does… or it should.
The purpose of this study was to estimate the total annual societal cost of uterine fibroid tumors in the United States, based on direct and indirect costs that include associated obstetric complications.|A systematic review of the literature was conducted to estimate the number of women who seek treatment for symptomatic fibroid tumors annually, the costs of medical and surgical treatment, the amount of work time lost, and obstetric complications that are attributable to fibroid tumors. Total annual costs were converted to 2010 US dollars. A sensitivity analysis was performed.|The estimated annual direct costs (surgery, hospital admissions, outpatient visits, and medications) were $4.1-9.4 billion. Estimated lost work-hour costs ranged from $1.55-17.2 billion annually. Obstetric outcomes that were attributed to fibroid tumors resulted in a cost of $238 million to $7.76 billion annually. Uterine fibroid tumors were estimated to cost the United States $5.9-34.4 billion
Uterine fibroids are the most common benign uterine tumours present in women of reproductive age. Mifepristone (RU-486) competitively binds and inhibits progesterone receptors. Studies have suggested that fibroid growth depends on the sexual steroids. Mifepristone has been shown to decrease fibroid size. This review summarises the effects of mifepristone treatment on fibroids and the associated adverse effects as described in randomised controlled trials.|To determine the efficacy and safety of mifepristone for the management of uterine fibroids in pre-menopausal women.|We searched the specialised register of the Cochrane Menstrual Disorders and Subfertility (Cochrane Menstrual Disorders and subfertility Review Group), the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2011, Issue 4), MEDLINE, EMBASE, PsycINFO, and CINAHL (to November 2011). We handsearched a number of journals, and searched reference lists, databases of ongoing trials and the Internet.
Uterine leiomyomas (fibroids) are the most common tumors in women of reproductive age and a cause of significant morbidity in this patient population. Depending on the fibroid location, they can be the cause of a variety of symptoms, such as abnormal uterine bleeding, constipation, urinary frequency, and pain. Historically, hysterectomy has been the primary treatment option, and uterine fibroids remain the leading cause for hysterectomy in the United States. However, women who do not wish to undergo hysterectomy now have a variety of less invasive options available, including uterine artery embolization. This article discusses uterine artery embolization as well as some of the other treatment strategies for symptomatic uterine fibroids. In many situations, there may be no single best treatment option but several viable alternatives. Each option is discussed with consideration of outcomes, complications, and, when possible, cost-effectiveness. The recommendations in this article are
To investigate how uterine artery embolization (UAE) might alter the risk profile for pregnancies complicated by fibroids.|Systematic literature review and meta-analysis of existing studies.|Academic reproductive medicine unit.|Women with fibroids.|A systematic literature review, raw data extraction, and data analysis.|Rates of miscarriage, preterm delivery, malpresentation, intrauterine growth restriction (IUGR), cesarean delivery, and postpartum hemorrhage (PPH).|Two hundred twenty-seven completed pregnancies after UAE were identified. Miscarriage rates were higher in UAE pregnancies (35.2%) compared with fibroid-containing pregnancies matched for age and fibroid location (16.5%) (odds ratio [OR] 2.8; 95% confidence interval [CI] 2.0-3.8). The UAE pregnancies were more likely to be delivered by cesarean section (66% vs. 48.5%; OR 2.1; 95% CI 1.4-2.9) and to experience PPH (13.9% vs. 2.5%; OR 6.4; 95% CI 3.5-11.7). Rates of preterm delivery (14% vs. 16%; OR 0.9; 95% CI 0.5-1.5), IUGR
Uterine leiomyomas (fibroids), the most common benign tumor in women of childbearing age, can cause symptoms including dysmenorrhea, menorrhagia, urinary symptoms, pain and infertility. Hysterectomy is a common approach to treating uterine fibroids, and less invasive surgical approaches such as myomectomy and uterine artery embolization also have been shown to alleviate symptoms. Magnetic resonance-guided focused ultrasound surgery (MRgFUS) is the only totally non-invasive surgical approved method for treating uterine fibroids. In clinical trials, MRgFUS resulted in significant relief of uterine fibroid symptoms. The safe and effective use of MRgFUS is affected by fibroid type and location, position relative to adjacent anatomical structures and the presence of co-existent pelvic disease. Additionally, successful outcomes with MRgFUS have been correlated with the volume of fibroids ablated during the procedure. Thus, selection of patients in whom sufficient fibroid volumes can be
Full Text View. Uterine Fibroid Pregnancy Registry. This study has been terminated. ... Purpose. The Uterine Fibroid Pregnancy Registry is a USA and European-based registry designed to monitor pregnancies in women with uterine fibroids in order to.
Full Text View. Laparoscopic Occlusion of Uterine Vessels Compared to Uterine Fibroid Embolization for Treatment of Uterine Fibroids. ... NCT00277680. Purpose. Women with symptomatic uterine fibroids are treated either by Uterine Fibroid Embolization (
Mifeprex shrinks fibroid tumors and improves the pain of endometriosis. Because the two drugs are chemically similar and have similar effects on the menstrual cycle, it is thought that CDB-2914 ... Repeat transvaginal ultrasound after 4-6 weeks of study
of in vitrofertilization ( IVF), to provide guidelines on the number of embryos to transfer in IVF-embryo transfer ( ET) in order to optimize healthy live births and minimize multiple pregnancies. ... Search terms included embryo transfer ( ET),
other disorders - associated with the PDGFRA gene. PDGFRA gene mutations that lead to a constitutively active PDGFRA protein are also associated with inflammatory fibroid polyps, which are small, noncancerous ( benign) tumors
First, Plan B was only available OTC to women age 17 and up. In April, a judge ordered that it be made available to women of all ages. Now, an appeals court judge has stayed an order that would make a one-dose version of the emergency contraception available to all ages, while allowing the two-dose drug to be sold OTC without restriction. What do you make of all this?
muscle pain relief in Hong kong eToims is a non-invasive pain therapy treatment for individuals desiring general physical health maintenance and enhancement or relief from chronic pain.Back pain is often caused or aggravated by bad or worn-out mattresses. A new pressure-relieving mattress and pillow can make a huge difference. It can support your back, shoulders and neck where it needs it most and thereby help you sleep in a better position, relieving pressure points and back pain. For more information on pressure relieving mattresses and pillows click here.For more information visit us at- Email-info@etoims.com,Contact- +1 215-387-0550.
For the past few months, I have not received any posts on the listserv OB-GYN-L. I would get daily posts in my e-mail. Where has it gone, what has happened to it? What can I do to get back on the list?
If anybody has any information, send me a note at:
Pregnant woman and the newborn infant in breast feeding both of them need safety. So, caution in use of drugs in pregnancy and during lactation is mandatory. The knowledge of risk-benefit ratio of different drugs should be in mind of the doctor while prescribing a pregnant or lactating lady.Definitions of Pregnancy categories of drugs and a table showing pregnancy categories of drugs and safety of drugs in lactation are given here.
Definitions of Pregnancy categories of drugs:
On the basis of the potentiality for producing birth defects drugs in pregnancy are grouped into 1 of 5 categories which are A,B, C, D and X. Drugs of class A and B are considered safe and can be used routinely.
Pregnancy Category A : Controlled studies in pregnant women fail to detect risk to the fetus in the first trimester and no evidence of risk in later trimesters. The possibility of harm to the fetus appears remote by using the drugs of pregnancy category A.
Pregnancy Category B : Presumed safety on the basis of animal studies, with no controlled study in pregnant women, or animal studies have shown an adverse effect which was not confirmed in controlled studies in women in the first trimester and there is no evidence of risk to the fetus in later trimesters.
Pregnancy Category C : Studies in women and animals are not available or studies in animals have shown adverse effects on the fetus and there is no controlled study in women. Drugs should be given in pregnancy only if the potential benefits justify the potential risk to the fetus.
Pregnancy Category D : There is positive evidence of risk to the human fetus (unsafe), however in a life-threatening illness the potential risk may be justified if there are no other alternatives.
Pregnancy Category X : Highly unsafe: risk of use outweighs any potential benefit. Drugs in this category are contraindicated in pregnant women or in a woman who may become pregnant. To get more please visit - http://medicalforall.net/drugs-pregnancy-lactation/
Recently, I had the occasion to review a case of a term primigravida with PROM in a private hospital (no housestaff or in house obstetricians). She was seen by an obstetrician soon after arrival, evaluated, and pitocin induction begun.
She did not deliver for around 29 hours after admission, and the delivering obstetrician (a different physician) was physically present during the last 2 hours of labor prior to delivery.
Simply put, while the two involved obstetricians were in communication by phone with the nursing staff throughout labor (separately as their "shifts" did not overlap), no one actually came to the bedside and wrote a note) from admission until around 2 hours before delivery.
Medical staff bylaws call for a daily progress note; this bylaw was easily met.
In reviewing the case, it did not "feel good" that no one came to the bedside.
My questions:
1. Does anyone have or know of any guidelines to mandate such bedside attendance? Of course, we all hope that the involved physicians would not need said guidelines. 2. Does anyone have a suggestion of hospital/nursing protocols? Simply, in this case I would like to have had a charge nurse or bedside nurse simply say, "Hey, no one has been by for a while. What's up?"
Reviews Of Progress is a weekly peer-reviewed scientific journal that covers original research and reviews. It publishes all articles under the guidance of the editorial team. The current Editor-in-Chief is Pindipol S.I, the editorial office is in Solapur.
I helped another physician with removal of a retained placenta last night, we were unsuccessful in removing it vaginally, her cervix was too closed to allow manual removal and we could only get a few pieces out with ring forceps and a large curette, so we did a laparotomy/hysterotomy and were able to preserve the uterus. The placenta turned out not to be an accreta and it was easily removed via that route through a low vertical incision on the uterus. Any thoughts on the appropriate CPT code would be appreciated. The patient came in through the ER five days after home delivery by her husband. She was severely anemic, rcvd 7 units of blood and is still quite ill and in the ICU but improving.
Has anyone tried FetalGrowth app (App Store for iPhone/iPad) ? I'm interested in using a simple and handy tool to calculate fetal percentiles, and I came across this app, which seems it does the job (plots growth charts, as well). I haven't seen anything else, besides this app, so I was wondering if there are people who have already tried it.
Had a case the other day with the above finding on a pap. She was age 36 and had a Mirena in place. How do people feel about the idea of trying to do an EMB with an IUD in place? If not, how do we proceed?
To all the members of OB-GYN-L… Thank you for coming! I’m thrilled that you’ve decided to check out the new Forum site, and look forward to reading about what’s on your mind.
If you’re new to the ObGyn.net community... welcome aboard! You’ve just joined an outstanding group of physicians and health care professionals who have been sharing information, answering questions, and building professional relationships via the site’s listserv for nearly 20 years.
Feel free to poke around on the site to get a feel for things, or take a look at the Help Topics page for instructions on how to use the different features of the site.
A few quick tips: For those of you who like getting new Forum messages delivered directly to your inbox, the first thing you’ll want to do is click on the ‘Follow this forum’ button on the main page. You’ll have the option of getting notifications immediately, as a daily digest, a weekly digest, or only when you’re not online (which is to say, if you’re on the site when someone posts a message, you won’t be notified of it). You won’t be able to post on the site just by replying to the email, but the message will contain a link that takes you directly to the message you’d like to reply to.
You can also follow individual conversations without following the whole list by going into the topic and clicking the ‘Follow this topic’ button next to the title.
Also, in ‘My Profile’ you can:
Enter your professional information, including specialty, subspecialty, and education (by clicking ‘Edit my profile’)
See your activity on the Forum, such as what discussions you have initiated or replied to, content you’ve ‘liked,’ and activity of people you’ve made your friends
In ‘My Settings’ you can:
Add or change your photo
Edit your birthday, gender, interests, location
Create a signature for your posts
Change the types of content you get notifications for, or change the way you receive notifications
If you have questions, feel free to respond to this post or send me a direct message by clicking on the envelope icon.
There are a variety of complications that can occur during laparoscopic surgery. In this tutorial learn some of the complications and tips to avoid them.
CC is a 31 year old primigravida who was referred for ultrasound at a community hospital due to suspected cardiac anomalies noted on a screening sonogram at her doctor's office. Due to concern about a probable cardiac abnormality an amniocentesis was performed at the local hospital.
Single umbilical artery color doppler, transverse scan of urinary bladder shows single umbilical artery (left), transverse section of umbilical cord showing only two vessels: one vein and one artery (right).
Key Differences between FQHCs and RHCs Chastity Werner, RHIT, June 13, 2013 FQHCs and RHCs take up a unique niche among physician practices. And that affects compensation and billing.
Improving Care Coordination in Your Practice Susanne Madden, June 12, 2013 Practices are feverishly working to control the rising costs of healthcare - effective care coordination can help.
Refunding Overpayments: Two Options for Medical Practices Ericka L. Adler, June 12, 2013 Medicare and Medicaid providers must return overpayments once identified. Here are two different refund approaches for practices to consider when necessary.
iPad Alternatives for Mobile Physicians Marisa Torrieri, June 11, 2013 As more physicians are seeing the merits of media tablets, the market is expanding, too.
B mode and 3D Ultrasound images of a fetal abdomen (35wks) revealing gallbladder calculi
This case study shows a 26 week gestation with a cystic mass close to the sacrum.
CC is a 31 year old primigravida who was referred for ultrasound at a community hospital due to suspected cardiac anomalies noted on a screening sonogram at her doctor's office. Due to concern about a probable cardiac abnormality an amniocentesis was performed at the local hospital.
Single umbilical artery color doppler, transverse scan of urinary bladder shows single umbilical artery (left), transverse section of umbilical cord showing only two vessels: one vein and one artery (right).
Normal 35 week pregnancy
